These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 5004903)

  • 1. [Potentiation of the hypoglycemic effect of sulfonylurea derivatives by drugs. II. Pharmacokinetics and metabolism of glibenclamide (HB 419) in presence of phenylbutazone].
    Schulz E; Koch K; Schmidt FH
    Eur J Clin Pharmacol; 1971 Dec; 4(1):32-7. PubMed ID: 5004903
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolism and kinetics of the hypoglycemic agent glipizide in man--comparison with glibenclamide.
    Fuccella LM; Tamassia V; Valzelli G
    J Clin Pharmacol New Drugs; 1973; 13(2):68-75. PubMed ID: 4631138
    [No Abstract]   [Full Text] [Related]  

  • 3. [Studies on the bioavailability of glibenclamide].
    Rupp W; Christ O; Fülberth W
    Arzneimittelforschung; 1972 Feb; 22(2):471-3. PubMed ID: 4623702
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of the pharmacokinetics of glipizide and glibenclamide in man.
    Balant L; Fabre J; Zahnd GR
    Eur J Clin Pharmacol; 1975; 8(1):63-9. PubMed ID: 823030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride.
    Kramer W; Müller G; Girbig F; Gutjahr U; Kowalewski S; Hartz D; Summ HD
    Biochim Biophys Acta; 1994 May; 1191(2):278-90. PubMed ID: 8172913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of glipizide in man: influence of renal insufficiency.
    Balant L; Zahnd G; Gorgia A; Schwarz R; Fabre J
    Diabetologia; 1973 Sep; ():331-8. PubMed ID: 4772979
    [No Abstract]   [Full Text] [Related]  

  • 7. Interaction of fluorescein derivatives with sulfonylurea binding in insulin-secreting cells.
    Schwanstecher M; Bachmann C; Löser S; Panten U
    Pharmacology; 1995 Mar; 50(3):182-91. PubMed ID: 7746835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human pharmacokinetics and metabolism of 14C-labeled gliquidone (AR-DF 26)].
    Kopitar Z
    Arzneimittelforschung; 1975 Sep; 25(9):1455-60. PubMed ID: 1103897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets.
    Schwanstecher M; Mnner K; Panten U
    Pharmacology; 1994 Aug; 49(2):105-11. PubMed ID: 7972319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics.
    Geisen K; Hitzel V; Okomonopoulos R; Pünter J; Weyer R; Summ HD
    Arzneimittelforschung; 1985; 35(4):707-12. PubMed ID: 3925960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metabolism of glibornuride in the human].
    Bigler F; Quitt P; Vecchi M; Vetter W
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2191. PubMed ID: 4679249
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacokinetics of radioactively labeled glisoxepide in the animal].
    Kolb KH; Schulze PE; Speck U; Acksteiner B
    Arzneimittelforschung; 1974 Mar; 24(0):397-403. PubMed ID: 4211553
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics and metabolism of 14C-glipentide, a new antidiabetic, after oral and intravenous administration.
    Chanal JL; Calmette MT; Khiat M; Rimbau V; Vera A
    Arzneimittelforschung; 1977; 27(4):852-6. PubMed ID: 577463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3).
    Boileau P; Wolfrum C; Shih DQ; Yang TA; Wolkoff AW; Stoffel M
    Diabetes; 2002 Dec; 51 Suppl 3():S343-8. PubMed ID: 12475773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition and oxidative metabolism of phenylbutazone in man.
    Aarbakke J; Bakke OM; Milde EJ; Davies DS
    Eur J Clin Pharmacol; 1977; 11(5):359-66. PubMed ID: 880975
    [No Abstract]   [Full Text] [Related]  

  • 16. Determination of 14C-bumadizone and 14C-phenylbutazone in the systemic blood, the blood of the portal vein, the intestinal lymph and the bile of cats after intrajejunal administration.
    Seebald H; Forth W
    Arzneimittelforschung; 1977; 27(4):804-9. PubMed ID: 577456
    [No Abstract]   [Full Text] [Related]  

  • 17. Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription.
    Steri R; Kara M; Proschak E; Steinhilber D; Schneider G; Schubert-Zsilavecz M
    Future Med Chem; 2010 Apr; 2(4):575-86. PubMed ID: 21426008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics of glibornuride].
    Rentsch G; Schmidt HA; Rieder J
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2209. PubMed ID: 4679250
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacokinetics and metabolite spectrum of glisoxepide in humans].
    Speck U; Mützel W; Kolb KH; Acksteiner B; Schulze PE
    Arzneimittelforschung; 1974 Mar; 24(0):404-9. PubMed ID: 4408089
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs.
    Balant L
    Clin Pharmacokinet; 1981; 6(3):215-41. PubMed ID: 7016385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.